Progress in the treatment of neovascular age-related macular degeneration

Ya-Xin Wang; Xiao-Yun Ke; Yan-Xia Chen; Bin Hu

doi:10.3980/j.issn.1672-5123.2021.10.14

Guoji Yanke Zazhi (Oct 2021)

Progress in the treatment of neovascular age-related macular degeneration

Ya-Xin Wang,
Xiao-Yun Ke,
Yan-Xia Chen,
Bin Hu

Affiliations

Ya-Xin Wang: Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China
Xiao-Yun Ke: Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China
Yan-Xia Chen: Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China
Bin Hu: Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China

DOI: https://doi.org/10.3980/j.issn.1672-5123.2021.10.14
Journal volume & issue: Vol. 21, no. 10
pp. 1732 – 1735

Abstract

Read online

Age-related macular degeneration(ARMD)is an important cause of visual impairment in people over 65 years old in western countries. It is the third leading cause of blindness in China and mainly affects central visual acuity. Vascular endothelial growth factor(VEGF)plays an important role in the pathogenesis of ARMD. Currently, intravitreous injection of anti-VEGF agents has been considered as the first-line treatment for ARMD. However, some patients still need repeated injection, or response negatively to anti-VEGF agents. Therefore, it is necessary to explore novel therapy to improve clinical outcomes and provide insights for neovascular ARMD treatment.

Published in Guoji Yanke Zazhi

ISSN: 1672-5123 (Print)
Publisher: Press of International Journal of Ophthalmology (IJO PRESS)
Country of publisher: China
LCC subjects: Medicine: Ophthalmology
Website: http://ies.ijo.cn/

About the journal

Abstract

Keywords